In our experiments, the extent of apoC3 suppression was comparable to, or greater than, that achieved with Volanesorsen, raising the possibility that profound reductions in apoC3 may contribute mechanistically to platelet activation and, ultimately, thrombocytopenia. The gene discussed is APOC3; the disease is Thrombocytopenia.